Monosaccharide-labeled nanoliposome drug delivery system, preparation method thereof and application thereof as a drug targeted delivery carrier
By preparing monosaccharide-labeled nanoliposomes and utilizing glucose carrier proteins to target cancer cells for drug endocytosis, the problems of lack of specificity of anticancer drugs and drug resistance of cancer stem cells have been solved, achieving highly effective treatment with reduced side effects.
Patent Information
- Application Number
- CN201980096444.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-05-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-05-23
AI Technical Summary
Existing anticancer drugs lack cancer specificity, which leads to the need to increase the dosage of chemotherapy drugs during treatment, increasing the risk of side effects on patients' bodies, and cancer stem cells developing drug resistance.
Cholesterol labeled with monosaccharide molecules was synthesized and combined with phospholipids to prepare nanoliposomes. These nanoliposomes were then used to target cancer cells with glucose carrier proteins, endocytose drugs into the cells, and carry anticancer drugs.
To enhance the efficacy of anticancer drugs in cancer cells and cancer stem cells, inhibit stem gene expression, improve treatment effectiveness, reduce side effects, and synergize with clinical anticancer drugs and radiotherapy.
Smart Images

Figure CN113840624B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a nanoliposome drug delivery system, and more particularly to a nanoliposome having a monosaccharide ligand labeled on its surface, wherein the monosaccharide ligand is bound to a cholesterol molecule embedded in the bilayer membrane of the nanoliposome. Background Art
[0002] Liposomes (also known as liposomes or liposomes) are pharmaceutical formulations that utilize vesicles formed by a phospholipid bilayer membrane to encapsulate drug molecules. Because the basic structure of biological plasma membranes is also a phospholipid bilayer, liposomes have a structure similar to that of biological cells and possess excellent biocompatibility. Although liposomes are now widely used as a drug delivery system, if liposomes lack targeting capabilities, they cannot effectively deliver active drugs (such as anticancer drugs) to the affected area (e.g., tumor cells), requiring an increased dosage to achieve the desired therapeutic effect.
[0003] Prior art attempts to link certain recognition molecules (so-called targeting ligands) to liposomes, allowing the liposomes to specifically release drugs in targeted areas through the specific interaction of the ligands with corresponding receptors on the surface of target cells. Commonly known targeting ligands include sugars, vitamins, lectins, peptide hormones, antigens, antibodies, and other proteins. For example, U.S. Patent No. 7,070,801 attempted to selectively deliver liposomes to target tissues or cells by linking sugars to the liposome surface. However, this approach required the use of a linker protein, such as human albumin, pre-bound to the liposome surface.
[0004] U.S. Patent No. 8,802,153 B2 discloses a selective drug delivery system, which encapsulates the anticancer drug paclitaxel in a nanoparticle composed of a copolymer of polyethylene glycol (PEG) and polylactic acid (PLA), wherein a molecule (Apt) for targeting prostate cancer-specific membrane antigen (PSMA) is attached to the nanoparticle, and PEG is used as a linker to link the Apt ligand to the outermost layer of the nanoparticle. U.S. Patent No. 8,747,891 B2 discloses a ceramide anionic liposome for encapsulating hydrophilic chemotherapy drugs, wherein the liposome comprises at least one PEG-modified neutral lipid (at least half of which is PEG (750) C8), at least one anionic lipid, a ceramide, and a cationic or neutral lipid, and the resulting ceramide anionic liposome must have a net negative charge under physiological pH conditions. Although modifying liposomes with PEG helps increase stability and prolong circulation time in the blood, recent research results have shown that PEG can interfere with the binding of ligands on the liposome surface to markers on target cells.
[0005] US Patent Application No. US 2017 / 0112800 A1 discloses a hydrophobic taxane-lipid covalent conjugate that provides additional stabilization of the liposome by generating supramolecular assembly within the lipid bilayer, leading to increased intratumoral drug concentration and thus enhancing its therapeutic efficacy. However, this application does not specifically describe the technical content related to the preparation of targeted liposomes by conjugating a targeting ligand to cholesterol.
[0006] The main problems facing cancer treatment today are that many anti-cancer drugs are not cancer-specific, and cancer stem cells can develop drug resistance and radiation resistance during treatment. This necessitates increasing the dose of chemotherapy drugs and radiation exposure during cancer treatment, which in turn increases the risk and probability of harmful side effects in the patient's body.
[0007] Therefore, the present invention first synthesizes a cholesterol conjugated to a monosaccharide or its derivative molecule and formulates it with at least one phospholipid to produce a monosaccharide-labeled nanoliposome. The resulting monosaccharide-labeled nanoliposome can be used as a delivery vehicle for anticancer drugs (e.g., ceramide) to prevent or treat cancer stem cells' resistance to these chemotherapeutic drugs. Summary of the Invention
[0008] Based on the above objectives, the present invention has discovered that the glucosamine-labeled nanoliposomes carrying ceramide, prepared according to the method of the present invention, have the ability to target cancer cells and cancer stem cells; can enhance the efficacy of anticancer drugs in cells; the released drugs can inhibit the expression of stemness genes in cancer stem cells; and, when combined with clinical anticancer drugs or radiotherapy, can enhance the efficacy of these therapies for the target cancer.
[0009] Therefore, one aspect of the present invention relates to a monosaccharide-labeled nanoliposome drug delivery system, comprising at least one cholesterol conjugated to a monosaccharide molecule and a phospholipid. The nanoliposome drug delivery system with surface-labeled monosaccharide molecules may also comprise unmodified cholesterol.
[0010] In a specific embodiment of the present invention, the cholesterol conjugated to the monosaccharide molecule is located within the bilayer membrane structure of the liposome, while the monosaccharide molecule is exposed on the surface of the liposome. This nanoliposome drug delivery system can effectively target the glucose transporter 1 (GLUT1) protein, which is highly expressed on the surface of cancer cells or cancer stem cells. GLUT1 is then internalized into the cell via endocytosis, allowing the drug to be delivered to the cancer cells or cancer stem cells.
[0011] In one embodiment of the present invention, the size of the nanoliposomes is between 80-150 nm and has a surface charge between -10 and -45 mV.
[0012] In some embodiments of the present invention, the phospholipids may be neutral lipids, which refer to any lipid that is uncharged or in a neutrally charged zwitterionic form at physiological pH. Examples of neutral lipids include, but are not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), distearoylphosphatidylethanolamine (DSPE), dipalmitoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), cephalins, cerebrosides, diacylglycerols, and sphingomyelin. Furthermore, the phospholipids may also be anionic lipids, which refer to any lipid that has a negative charge at physiological pH. Examples of anionic lipids include, but are not limited to, dihexadecene phosphate (DHDP), phosphatidylinositol (PI), phosphatidylserine (PS) such as dimyristoylphosphatidylserine (DMPS), dipalmitoylphosphatidylserine (DPPS), phosphoglycerols (PG) such as dimyristoylglycerol (DMPG), dioleoylphosphatidylglycerol, dioleoylphosphatidylglycerol (DOPG), dilaurylphosphatidylglycerol (DLPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), phosphatidic acids (PA) such as dimyristoyl phosphate (DMPA), dipalmitoyl phosphate (DPPA), and diphosphatidylglycerol (DPG), and the like.
[0013] In other embodiments of the present invention, the monosaccharide molecule is a monosaccharide molecule that can be conjugated with cholesterol, such as glucose, fructose, galactose, mannose, etc. or their derivatives, preferably glucose or glucose derivatives (such as glucosamine).
[0014] In one embodiment of the present invention, the monosaccharide molecule-labeled nanoliposome drug delivery system may further comprise an anticancer drug, including a hydrophilic anticancer drug or a hydrophobic anticancer drug.
[0015] In one embodiment of the present invention, the nanoliposome drug delivery system of the present invention can be used to carry at least one chemotherapeutic drug in its hollow cavity. The monosaccharide-labeled nanoliposome drug delivery system can also be combined with a drug embedded in the lipid bilayer of the delivery system to form a targeted therapy nanodrug liposome in which the drug is embedded in the lipid bilayer. For example, in one embodiment of the present invention, ceramide is carried in the monosaccharide-labeled nanoliposome of the present invention to prepare a monosaccharide-labeled ceramide nanoliposome, wherein the ceramide is embedded in the bilayer membrane structure of the liposome. The nanodrug liposome in this embodiment can also further contain other drugs in its hollow cavity, becoming a liposome capable of targeted therapy and carrying multiple drugs in the lipid bilayer and hollow cavity.
[0016] In some embodiments of the present invention, the targeted therapy nano-drug liposomes or ceramide nano-liposomes can carry at least one anticancer drug in the hollow cavity of the liposome, such as (but not limited to) doxorubicin, epirubicin, bleomycin, mitomycin C, 5-fluorouracil, cyclophosphamide, camptothecin, cisplatin, carboplatin, oxaliplatin, paclitaxel, and European paclitaxel. (Docetaxel), Gemcitabine, Vinorelbine, Irinotecan, Etoposide, Vinblastine, Pemetrexed, Hydroxyurea, Methotrexate, Capecitabine, Floxuridine, Cabazitaxel, Mitoxantrone, Estramustine, Curcumin, camptothecin derivative SN-38, and combinations thereof.
[0017] In other embodiments of the present invention, the targeted therapy nano-drug liposomes or ceramide nano-liposomes can be used to prevent or treat cancer stem cells' resistance to the anticancer drug.
[0018] Another aspect of the present invention relates to a method for preparing surface-labeled monosaccharide-labeled nanoliposomes, comprising: synthesizing a monosaccharide-modified cholesterol; mixing a phospholipid, the monosaccharide-modified cholesterol, and optionally unmodified cholesterol with a drug; and producing single lipid bilayer liposomes of a predetermined size using a thin film hydration method, a solvent dispersion method, an organic solvent injection method, a surfactant method, a thin film extrusion method, a French high-pressure method, or the like.
[0019] In some embodiments of the present invention, the phospholipid, monosaccharide-modified cholesterol and drug are mixed in a ratio of 42-70 mmole% of dipalmitoylphosphatidylcholine (DPPC), 20-28 mmole% of monosaccharide-modified cholesterol and 10-30 mmole% of ceramide.
[0020] In another embodiment of the present invention, the monosaccharide-modified cholesterol is glucosamine-modified cholesterol.
[0021] Yet another aspect of the present invention relates to a pharmaceutical composition, preferably for use in cancer treatment, including but not limited to cancer stem cell therapy, drug-resistant cancer cell therapy, radiation-resistant cancer cell therapy, and combinations thereof. The pharmaceutical composition comprises: a monosaccharide-labeled drug delivery system, a targeted therapy nanoparticle liposome, carrying an anticancer drug; and a pharmaceutically acceptable base, carrier, or excipient.
[0022] In some embodiments of the present invention, the anticancer drug may be a ceramide and / or a chemotherapeutic drug. The pharmaceutical composition may be formulated with a pharmaceutically acceptable base material, carrier, or excipient according to methods known in the pharmaceutical art into dosage forms suitable for various administration routes, such as (but not limited to) solutions, drops, pills, tablets, powders, emulsions, transdermal dressings, ointments, creams, and drug-containing stents.
[0023] The pharmaceutically acceptable base material, carrier or excipient can be any one of ordinary skill in the pharmaceutical field.
[0024] In some embodiments of the present invention, examples of the pharmaceutically acceptable base material include polysaccharides, proteins, synthetic polymers or mixtures thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 FIG1 is a transmission electron microscopy image of glucosamine-labeled nanoliposomes prepared according to an example of the present invention under physiological conditions, showing that the nanoliposomes are spherical structures with a lipid bilayer membrane.
[0026] Figure 2 The stability of glucosamine-labeled nanoliposomes of the present invention in PBS buffer was measured by DSL (upper half) and TEM (lower half). The liposomes were stained with uranyl acetate (2 wt%) after 35 days of storage. The scale bar is 100 nm.
[0027] FIG3 shows that the glucosamine-labeled nanoliposomes of the present invention enter into non-small cell lung cancer cell spheres (H1299 non-small lung cancer, Figure 3A ) and colorectal cancer cell spheres (DLD-1colon cancer, Figure 3B ) in conjugate electron microscope image.
[0028] Figure 4 shows that glucosamine-labeled nanoliposomes of the present invention enhance cellular uptake of ceramide. (A) A549 non-small cell lung cancer stem cell tumor spheres (A549CSCsspheres) treated with glucosamine-labeled ceramide liposomes for 12 hours demonstrate high uptake into the spheres, with effective accumulation deep within the spheres (anaerobic zone). The scale bar represents 50 μm. (B) Flow cytometry analysis demonstrates that Cy5.5-labeled nanoliposomes are more efficiently taken up into A549 non-small cell lung cancer stem cell tumor spheres.
[0029] Figure 5 shows the accumulation of glucosamine-labeled ceramide liposomes in various organs and tumors in animals during in vivo experiments, as well as their accumulation within tumor tissue. (A) Non-invasive in vivo imaging revealed that Cy5.5-glucosamine-labeled nanoliposomes accumulated more efficiently in tumor tissue and less in other organs. (B) Confocal fluorescence microscopy, plan, 3D, and cross-sectional images revealed that Cy5.5-glucosamine-labeled nanoliposomes more efficiently penetrated tumor tissue and accumulated in anaerobic areas. Scale bar represents 100 μm.
[0030] Figure 6 This figure shows that glucosamine-labeled ceramide liposomes can effectively inhibit the formation of tumor spheres from A549 non-small cell lung cancer stem cells. The scale bar represents 400 μm.
[0031] Figure 7 demonstrates the selective cytotoxicity of glucosamine-labeled ceramide liposomes to cancer stem cells. (A) Flow cytometric analysis revealed that treatment with glucosamine-labeled ceramide liposomes resulted in a higher percentage of apoptosis in A549 non-small cell lung cancer stem cell spheres. (B) Flow cytometric analysis revealed that glucosamine-labeled ceramide liposomes induced a higher rate of apoptosis in A549 parental cancer cells and A549 cancer stem cells compared to free ceramide, but had no effect on L929 normal fibroblasts. Glucosamine-labeled ceramide liposomes even induced a higher rate of apoptosis in A549 cancer stem cells than in A549 parental cancer cells.
[0032] Figure 8 shows that the sensitivity of A549 cancer stem cells to anticancer drugs (10 μM cisplatin and 5 μM paclitaxel) and radiation therapy (5 Gy and 10 Gy) was significantly increased in the presence of glucosamine-labeled ceramide liposomes. Conversely, the number of viable A549 cancer stem cells treated with glucosamine-labeled ceramide liposomes and simultaneous inhibition of retinoblastoma protein (RB) expression was significantly increased. Free ceramide represents A549 cancer stem cells treated with free ceramide; G5C3 represents A549 cancer stem cells treated with glucosamine-labeled ceramide liposomes; G5C3+shRB represents A549 cancer stem cells co-treated with glucosamine-labeled ceramide liposomes and shRNA targeting RB. The free ceramide and G5C3 groups were compared with the control group; the G5C3+shRB group was compared with the G5C3 group. (* or #: p < 0.05; ** or ##: p < 0.01).
[0033] Figure 9 shows that A549 cancer stem cells treated with glucosamine-labeled ceramide liposomes exhibit reduced cell migration and invasion abilities compared to control cells, but these abilities are restored by RB inhibition. Free ceramide represents A549 cancer stem cells treated with free ceramide; G5C3 represents A549 cancer stem cells treated with glucosamine-labeled ceramide liposomes; G5C3+shRB represents A549 cancer stem cells co-treated with glucosamine-labeled ceramide liposomes and shRNA targeting RB. The free ceramide and G5C3 groups are compared with the control group; the G5C3+shRB group is compared with the G5C3 group. (* or #: p < 0.05; ** or ##: p < 0.01).
[0034] FIG10 shows that glucosamine-labeled ceramide liposomes combined with cisplatin / paclitaxel treatment can inhibit tumor progression in vivo. Figure 10A The changes in relative tumor volume in mice indicate that the therapeutic effect of glucosamine-labeled ceramide liposomes is comparable to that of clinical anticancer drugs. Furthermore, the nanoliposomes of the present invention, when combined with clinical anticancer drugs, can significantly inhibit tumor growth. Figure 10B Figure 2 is the weight change of mice during the treatment period, indicating that the nanoliposomes of the present invention do not cause significant side effects.
[0035] Figure 11 H&E, Ki67, and caspase 3 staining were performed on tumor tissue sections treated with glucosamine-labeled ceramide liposomes and cisplatin / paclitaxel. These results demonstrate that the nanoliposomes, when combined with clinical anticancer drugs, effectively induce tissue necrosis within tumor tissue and inhibit tumor proliferation. The scale bar represents 200 μm.
[0036] FIG12 is a transmission electron microscopy image of glucosamine-labeled nanoliposomes prepared according to an example of the present invention under physiological conditions, showing that the nanoliposomes are spherical structures with a lipid bilayer membrane. Figure 12A Glucosamine-labeled ceramide nanoliposomes carrying cisplatin; Figure 12B Glucosamine-labeled ceramide nanoliposomes.
[0037] Figure 13 Transmission electron microscopy images of glucose-labeled ceramide nanoliposomes carrying paclitaxel prepared according to an embodiment of the present invention under physiological conditions show that the nanoliposomes are spherical structures with a lipid bilayer membrane. DETAILED DESCRIPTION
[0038] Other features and advantages of the present invention will be further illustrated and described in the following embodiments, which are only used as auxiliary explanations and are not intended to limit the scope of the present invention.
[0039] Example 1. Preparation of Nanoliposomes Labeled with Monosaccharide Molecules
[0040] Synthetic glucosamine-cholesterol
[0041] The preparation process is as follows:
[0042]
[0043] First, cholesterol-NHS esters were synthesized. Cholesterol (1 mmol), succinic anhydride (3 mmol), triethylamine (TEA, 1 mmol), and 4-dimethylaminopyridine (0.3 mmol) were dissolved in dry dichloromethane (DCM) and stirred at room temperature for 24 hours. The product (carboxy-cholesterol) was then extracted three times with saturated NaCl solution. The carboxy-cholesterol was dissolved in DCM, and the DCM was removed on a rotary evaporator.
[0044] Carboxyl-cholesterol (1mmol), N-hydroxysuccinimide (NHS, 1.5mmol) and 4-dimethylaminopyridine (0.3mmol) were dissolved in dry dichloromethane (DCM). The solution was added to a two-neck round-bottom flask equipped with a magnetic stirring bar, and nitrogen was introduced. N,N-dicyclohexylcarbodiimide (DCC, 3mmol) pre-dissolved in dry DCM was slowly added dropwise to the carboxyl-cholesterol solution (placed in a 0°C ice bath), and stirred under nitrogen for 24 hours. Afterwards, the product was filtered to remove the by-product DCU, and extracted three times with saturated NaCl solution. Cholesterol-NHS ester was dissolved in DCM, and then DCM was removed on a rotary evaporator. The resulting product is cholesterol-NHS ester 1 H NMR (chloroform-d): δ 0.6-2.4 (m, from cholesterol), 2.6 (t, -COO-CH 2 CH2-COOH from succinic acid), δ2.6(t,-COO-CH2CH 2 -COOH from succinic acid), δ2.843 (s, -CH 2 -CH 2 -from NHS), δ4.6-4.7 (m, -CH-O-from cholesterol), δ5.4 (m, -C=CH-from cholesterol).
[0045] Then, glucosamine (1.2 mmol) and the obtained cholesterol-NHS ester were dissolved in dimethyl sulfoxide (DMSO) / deionized water (volume ratio: 1:1) and placed in a glass bottle. After reacting for 24 hours, the product was extracted three times with saturated NaCl solution. Glucosamine-cholesterol was dissolved in DCM and the DCM solvent was removed on a rotary evaporator. 1 H NMR (DMSO-d6): δ2.5-92.65 (m, CCH2CH2C from succinic acid); δ0.6-2.4 (m, from cholesterol), δ2.6 (t, -COO-CH 2 CH2-COOH from succinic acid), δ2.6(t,-COO-CH 2 CH 2 -COOH from succinic acid), δ3.3-3.7 (s, -CH 2 - and -CH from glucose), δ 4.6-4.7 (m, -CH-O- from cholesterol), δ 5.4 (m, -C=CH- from cholesterol). The obtained product was also analyzed by SHIMADZU Fourier transform infrared spectrometer (KBr): 1176 cm -1 (COC elongation), 1258cm -1 (OC elongation), 1707cm -1(C=O elongation), 1793 cm -1 (C=O elongation), 2700-2900cm -1 (CH elongation), 2500-3300cm -1 (OH elongation).
[0046] Preparation of glucosamine-labeled nanoliposomes
[0047] Synthesized glucosamine-cholesterol (Glu-Chol), unmodified cholesterol, cholesterol modified with an NH2 functional group (Chol-NH2), and dipalmitoylphosphatidylcholine (DPPC) (at a molar ratio of 6.3:1.7:4.3:18.2) were dissolved in dichloromethane (DCM) and formed into a thin liquid film using a rotary evaporator at room temperature. A 60°C PBS aqueous solution (pH 7.4) was then added to rehydrate the film. The resulting solution was ultrasonically shaken (22,000 Hz) for 6 minutes. The solution was then filtered through a 0.22-μm PVDF membrane (Millipore, Darmstadt, Germany) twice and a 0.1-μm PVDF membrane (Millipore, Darmstadt, Germany) twice to obtain liposomes containing varying concentrations of glucosamine. After reacting with a Cy5.5-NHS ester aqueous solution for 2 days, the liposome was dialyzed using a MW6-8000 dialysis bag to remove unreacted Cy5.5 to obtain fluorescently labeled liposomes.
[0048] The appearance of the obtained glucosamine-labeled ceramide nanoliposomes was observed using a JEOL JEM-2000EX II transmission electron microscope (JEOL Inc., Peabody, MA) after staining with 2% uranyl acetate. Figure 1 Transmission electron microscopy images show that the nanoliposomes of the present invention can maintain a good intact morphology under physiological conditions and are a spherical structure with a lipid bilayer membrane.
[0049] The nanoliposomes of the present invention were placed in PBS at 4°C for 7, 35, and 42 days, and their particle size and size changes were measured by DSL. After 35 days of static culture, they were stained with 2wt% uranyl acetate and their appearance was observed under a TEM microscope to evaluate their stability. The results showed that the particle size and morphology of the ceramide nanoliposomes of the present invention remained stable after being stored at 4°C for more than one month ( Figure 2 ).
[0050] In this example, six groups of liposomes containing varying concentrations of glucosamine were prepared according to the liposome composition listed in Table 1. The analytical values in Table 1 indicate that these six groups of liposomes exhibited similar properties, with a measured particle size of approximately 120 nm, a PDI of approximately 0.2, and a surface charge (zeta) ranging from -3 to -15. Therefore, these liposomes can be used to investigate their ability to target anaerobic tumors.
[0051] Table 1. Particle size, surface charge, and polydispersity index (PDI) of nanoliposomes with different compositions
[0052]
[0053] The distribution of the glucosamine-labeled nanoliposomes of the present invention within H1299 non-small lung cancer (NSCLC) and DLD-1 colon cancer (DLD-1) cell spheroids was further investigated. The experimental method was briefly described as follows: Cy5.5-fluorescently labeled nanoliposomes prepared as described above were co-cultured with NSCLC or DLD-1 tumor spheroids for 5 hours. Pimonidazole (150 μM) was then added and incubated for 1 hour. The cells were then fixed with formalin and immunostained with a 1:100 dilution of FITC-mAb1. The distribution of the indicator fluorescence in the anaerobic zone was observed under a confocal laser scanning microscope (CLSM, Zeiss 880). The distribution of the fluorescent dye-labeled nanoliposomes within the tumor tissue was also observed using CLSM.
[0054] As shown in the conjugate electron microscopy images in Figure 3, as the concentration of glucosamine increases, the amount of glucosamine-labeled nanoliposomes that enter the cancer cell spheres also increases. In addition, the overlapping images of the HP-FITC anaerobic zone indicator and the fluorescently labeled Cy5.5-glucosamine-labeled nanoliposomes show that the glucosamine-labeled liposomes can be targeted to the tumor and accumulated in the anaerobic zone of the tumor. When the concentration of glucosamine-cholesterol is higher than 2.5 mmole, there is a significant difference (see Figure 3A 、 Figure 3B ).
[0055] Example 2: Glucosamine-labeled ceramide nanoliposomes and their targeting ability evaluation for cancer cells and cancer stem cells
[0056] Preparation: The synthesized glucosamine-cholesterol, the anticancer drug ceramide, and dipalmitoylphosphatidylcholine (DPPC) were dissolved in dichloromethane (DCM) at a molar ratio of 10.9:4.1:3.5. A thin film was formed using a rotary evaporator at room temperature. A 60°C PBS solution (pH 7.4) was then added to rehydrate the film. The resulting solution was ultrasonically shaken (22,000 Hz) for 6 minutes. The solution was then filtered through a 0.22-μm PVDF filter (Millipore, Darmstadt, Germany) twice and a 0.1-μm PVDF filter (Millipore, Darmstadt, Germany) twice, yielding surface-labeled ceramide nanoliposomes labeled with glucose molecules, designated G5C3, where G represents glucose and C represents ceramide. Different ceramide nanoliposomes can be prepared by varying the ratio of glucose to ceramide, as shown in Table 2.
[0057] Table 2. Particle size, surface charge, and polydispersity index (PDI) of ceramide nanoliposomes with different compositions
[0058]
[0059] a Particle size, surface charge (zeta-potential) and particle size dispersion (PDI) were determined by DLS.
[0060] Dynamic light scattering (DLS) analysis revealed that the glucose-labeled ceramide nanoliposomes with varying composition ratios had particle sizes ranging from approximately 100 to 150 nm (Table 2). The particle size dispersion index (PDI) value was approximately 0.2, indicating uniform size of the resulting ceramide nanoliposomes.
[0061] The surface charge of the nanoliposomes of the present invention was measured at 25°C using a particle size and molecular size analyzer 1000HSA (Spectris, UK). The surface charge of the ceramide nanoliposomes (G4C4 and G5C3) with high glucosamine content ranged from -10 to -45 millivolts (mV), and the ceramide encapsulation efficiency was approximately 97% by weight. The nanoliposomes of the present invention were incubated in PBS at 4°C for 7, 35, and 42 days, and their particle size and size changes were measured using DSL. Stability was assessed by staining with 2 wt% uranyl acetate and observing their appearance using a TEM microscope after 35 days of incubation. The results showed that the ceramide nanoliposomes of the present invention maintained stable particle size and morphology after storage at 4°C for more than one month.
[0062] Evaluation of the targeting ability of ceramide nanoliposomes on cancer cells and cancer stem cells:
[0063] Cancer stem cells (CSCs) are undifferentiated cells with the ability to self-renew. This example uses an in vitro tumor sphere model generated from suspended lung cancer cells to evaluate the targeting ability of the nanoliposomes of the present invention on cancer cells and cancer stem cells. 4 Surviving cells treated with drugs were plated on a culture dish covered with soft agar. This soft surface prevented the cells from attaching, resulting in the formation of spheroids suspended in the surrounding tissue. The number of spheroids was counted after 10 days.
[0064] The G5C3 nanoliposomes prepared in this example were reacted with Cy5.5-NHS ester for one day. Excess Cy5.5-NHS ester was then dialyzed against PBS to remove the resulting Cy5.5-G5C3 nanoliposomes. The resulting Cy5.5-G5C3 nanoliposomes were then co-cultured with A549 non-small lung cancer stem cell tumor spheres (A549CSCs spheres) for 5 hours. Pimonidazole, a hypoxia marker, was then added and incubated for 1 hour. The cells were then fixed with formalin and immunostained with FITC-mAb1 at a 1:100 dilution. Fluorescence distribution was observed under a confocal laser scanning microscope (CLSM, Zeiss 880).
[0065] The results of the conjugate laser scanning microscopy in FIG4 show that the ceramide nanoliposomes (G4C4 and G5C3) of the present invention can effectively target the glucose transporter 1 (GLUT1) highly expressed on the surface of cancer cells or cancer stem cells through the glucosamine labeled on their membranes, and are internalized into the cells via endocytosis, thereby delivering the carried ceramide to the cancer cells or cancer stem cells (see FIG4C4 and G5C3). Figure 4A 、 Figure 4B ).
[0066] Nanoliposomes containing fluorescent dye were prepared for in vivo tracking. The G5C3 nanoliposomes prepared in Example 1 were reacted with Cy5.5-NHS ester for one day, and then dialyzed with PBS to remove excess Cy5.5-NHS ester. H1299 cells (1×10 7Cells / 0.1 mL contained in basement membrane matrix gel (high concentration matrix gel, Corning) were subcutaneously injected into the back surface of four-week-old female nude mice. Four weeks after tumor cell transplantation, mice with H1299 tumors (tumor volume of about 500 mm) were 3 ), intravenously inject 0.1 mL of Cy5.5-G5C3 nanoliposomes (ceramide dose of 0.375 mg / kg -1 ) were treated with the Cy5.5-G5C3 nanoliposomes. 23 hours after drug injection, H1299 tumor-bearing mice were intraperitoneally injected with 0.1 mL of a hypoxia marker (pimonidazole) (40 mg / mL). One hour later, the in vivo distribution of Cy5.5-G5C3 nanoliposomes was observed using a XENOGEN IVIS imaging system (IVIS50, PerkinElmer).
[0067] Mice were sacrificed and their organs and tumors removed. Tumors were fixed with formalin-fixed Tissue-Tek OCT microscopes, and tissue sections were embedded and immunostained with FITC-mAb1 at a 1:100 dilution. Fluorescence distribution was then observed under a conjugate laser scanning microscope (CLSM, Zeiss 880). CLSM was used to observe the distribution of fluorescent dye-containing nanoliposomes within the tumor tissue.
[0068] The results in Figure 5 show that G5C3 nanoliposomes mostly accumulate in tumors and do not accumulate significantly in organs such as the brain and liver (see Figure 5A 、 Figure 5B ).
[0069] In addition, the sphere formation of the G4C4 and G5C3 nanoliposomes treated groups was reduced, which reflects that the CSC cells in these treated groups lost their anti-apoptosis and long-term self-renewal abilities ( Figure 6 ).
[0070] Example 3: Nanoliposomes labeled with sugar molecules selectively induce apoptosis in human lung cancer cells A549 CSC
[0071] This example further analyzes the apoptosis-inducing effect of the ceramide nanoliposomes of the present invention on cancer cells and cancer stem cells by Annexin V / PI staining. The cells were stained with 5 μL Annexin V-FITC and 5 μL propidium iodide (PI) (5 μg / ml) (BD Biosciences) in 1× binding buffer (10 mM HEPES, pH 7.4, 140 mM NaOH, 2.5 mm CaCl2) at room temperature for 15 minutes. The cells were passed through a Cytomics FC500 flow cytometer (Beckman Coulter) to measure the fluorescence of annexin V-FITC and PI to detect cell apoptosis. + / PI - ) and late apoptosis (annexin V + / PI + ) cells are defined as dead cells. The results of Annexin-FITC / PI staining showed that since the nanoliposomes of the present invention enhanced the delivery of ceramide, the apoptosis resistance of the suspended spheres was significantly inhibited when the cells were treated with G4C4 and G5C3 ( Figure 7A ).
[0072] To clearly demonstrate that glucose-labeled liposomal ceramide has selective cytotoxicity, the apoptotic effects of free ceramide and nanoliposome G5C3 of the present invention on normal L929 fibroblasts, parental lung cancer cells, and A549 CSC cells cultured under attachment conditions were determined.
[0073] Depend on Figure 7B Results showed that neither free ceramide nor G5C3 induced significant apoptosis in normal L929 fibroblasts. However, in parental lung cancer cells, the nanoliposomal G5C3 of the present invention exhibited a higher uptake rate and superior cytotoxicity compared to free ceramide. A549 CSCs are known to be resistant to free ceramide, but G5C3-treated CSCs displayed increased cytotoxicity, likely due to their greater reliance on glycolysis for energy compared to parental cells. Overall, the glucose-labeled ceramide liposomes of the present invention are indeed capable of exerting selective cytotoxic effects and broadly blocking CSCs' therapeutic resistance, without adversely affecting normal fibroblasts.
[0074] Example 4: Evaluation of Cancer Stem Cell Inhibition by Nanoliposomes Labeled with Sugar Molecules Combined with Clinical Anticancer Drugs / Radiotherapy
[0075] This example uses cisplatin and paclitaxel, two clinical drugs commonly used in lung cancer patients, to verify whether the drug resistance of lung cancer CSCs will be affected by co-administration of G5C3 liposomes. Figure 8A The results showed that CSCs treated with the G5C3 liposomes of the present invention were more sensitive to cisplatin and paclitaxel than those in the control group, and blocking the activity of RB inhibited this effect. In addition, the survival rate of CSCs treated with or without G5C3 liposomes at different radiation doses also showed that CSCs treated with the G5C3 liposomes of the present invention were more sensitive to radiation than those in the control group ( Figure 8B ). If RB expression is lost, CSCs will regain resistance to radiotherapy, even in the presence of the G5C3 liposomes of the present invention. In addition, G5C3 liposomes also inhibit the migration and invasion ability of lung CSCs ( Figure 9A , Figure 9B ), but reducing RB expression also rescued the metastatic potential of CSCs, indicating that inhibiting RB expression and activity can counteract the effects of G5C3 on CSCs. In other words, the G5C3-induced differentiation state and reduced CSC properties are RB-dependent. Taken together, these results suggest that the G5C3 liposomes of the present invention can synergistically inhibit CSC survival when combined with clinical anticancer drugs or radiotherapy, thereby helping to eliminate or reduce cancer stem cell resistance to anticancer drugs or radiotherapy and enhancing therapeutic efficacy.
[0076] Example 5. In vivo tumor inhibition evaluation of surface-labeled sugar nanoliposomes combined with anticancer drugs / radiotherapy
[0077] In this example, an in vivo tumor xenograft model was used to evaluate the in vivo tumor inhibition efficacy of the ceramide nanoliposomes of the present invention combined with anticancer drugs. H1299 CSCs and H1299 cancer cells (1×10 6 cells / 0.1mL) and Matrigel (Matrix high concentration) were co-injected into the back surface of four-week-old female nude mice for subcutaneous transplantation. One month after transplantation, mice with H1299 tumors (tumor volume of about 100mm) were transplanted. 3 ) were treated intravenously with carboplatin / paclitaxel (CP), G5C3 ceramide nanosomes, and a combination of carboplatin / paclitaxel and G5C3 nanosomes (each drug dose: 50 mg / kg carboplatin, 18 mg / kg paclitaxel, and 0.375 mg / kg ceramide). Tumor size (V) was measured every two days with a vernier caliper for 30 days to assess the antitumor activity of the drugs. V = a × b 2 / 2, where a and b are the long and short axes of the tumor, respectively. Thirty days after injection, mice were sacrificed and whole blood was collected for hematology analysis. Biochemical indices were assessed using an automated clinical chemistry analyzer (DRI-CHEM 4000i, FUJI) and a hematology analyzer (XT-1800iv, Sysmex).
[0078] The results showed that the combination of carboplatin / paclitaxel (CP) and the G5C3 nanoliposomes of the present invention had the most significant effect in inhibiting tumor growth ( Figure 10A After 26 days, the anti-tumor activity of the combination of carboplatin / paclitaxel (CP) and the G5C3 of the present invention was 9.6 times and 9.1 times that of the traditional CP treatment and the G5C3 liposome alone, respectively. The results of in vivo administration demonstrated that the G5C3 liposome has a strong anti-tumor activity and enhances the sensitivity of chemotherapy. In addition, the use of the G5C3 liposome of the present invention or its combination with carboplatin / paclitaxel did not significantly change the body weight of the mice ( Figure 10B ), which means that G5C3 can preserve normal cells while adversely affecting lung cancer cells without causing significant side effects in animals.
[0079] This example also used H&E, Ki-67 and caspase 3 staining of tumor tissues and observed them under a light microscope to assess the degree of tumor necrosis, proliferation and apoptosis. Figure 11 Staining of tumor tissue sections revealed only mild cell necrosis in the CP or G5C3-treated groups, while significantly more necrosis was observed in the combination treatment group with CP and G5C3. Histopathological staining with Ki-67 revealed normal tumor proliferation in the control group. However, the combination of CP and G5C3 significantly reduced cancer cell proliferation compared to the CP or G5C3 liposome-treated groups, as demonstrated by Ki-67 staining.
[0080] Furthermore, histopathological results using caspase-3 staining revealed that both G5C3 liposomes alone and the combination of CP and G5C3 significantly promoted cell apoptosis compared to the CP-treated group. These tumor histopathological staining results are consistent with the aforementioned in vivo antitumor efficacy results, demonstrating that the nanoliposomes of the present invention, when combined with clinically used anticancer drugs, can effectively induce tissue necrosis within tumor tissue, inhibit tumor proliferation, reduce tumor volume, and even achieve tumor eradication.
[0081] Example 6. Preparation of Glucose-Labeled Ceramide Nanoliposomes Carrying Cisplatin
[0082] Dipalmitoylphosphatidylcholine (DPPC), glucosamine-cholesterol synthesized as described in Example 1, cholesterol, and ceramide were added to a concentration bottle at the molar ratios shown in Table 2. 10 mL of DCM was added and mixed thoroughly. The DCM was removed using a cycloconcentrator, allowing a thin film to form at the bottom of the bottle. The solution was then placed in a vacuum oven for one day. Next, 9 mL of diethyl ether was added to dissolve the film at 40°C. Then, 3 mL of PBS (oil:water = 3:1 v / v) containing cisplatin at 60°C was added and rapidly mixed using a vortex mixer. The ether was removed using a cycloconcentrator, and the appropriate amount of PBS was added. The solution was then placed in a 60°C oven for 1 hour. Finally, the solution was filtered through 0.2 μm and 0.1 μm filters to obtain the cisplatin-loaded glucose-labeled ceramide target lipids. The obtained nanoliposomes were ceramide nanoliposomes with surface-labeled glucose molecules carrying cisplatin, numbered GC-PL; G-PL was nanoliposomes with surface-labeled glucose molecules carrying cisplatin; GC-L was ceramide nanoliposomes with surface-labeled glucose molecules; GL was nanoliposomes with surface-labeled glucose molecules; C-PL was ceramide nanoliposomes carrying cisplatin; and PL was nanoliposomes carrying cisplatin, where G represents glucose, C represents ceramide, and P represents cisplatin. The compositions of the individual nanoliposomes are shown in Table 3 below.
[0083] Table 3. Particle size, surface charge and polydispersity index (PDI) of nanoliposomes with or without ceramide (C) and / or cisplatin (P)
[0084]
[0085] a Particle size, particle size dispersion (PDI), and surface charge were measured using DLS.
[0086] The appearance of the obtained nanoliposomes was observed using a JEOL JEM-2000EX II transmission electron microscope (JEOL Inc., Peabody, MA) after staining with 2% uranyl acetate. FIG12 shows the results of transmission electron microscopy observation, which shows that the glucose-labeled cisplatin nanoliposomes obtained in this example with or without ceramide can maintain a good intact morphology under physiological conditions, with a spherical structure of lipid bilayer membrane and uniform size (see FIG12 ). Figure 12A and Figure 12B ).
[0087] The resulting glucose-labeled ceramide-targeted cisplatin-loaded liposomes were further analyzed for drug loading (DL) and encapsulation efficiency (EE). The prepared liposome solution was concentrated and centrifuged to remove unencapsulated drug, followed by freeze-drying to remove moisture. 2 mg of the dry powder was then weighed into a microcentrifuge tube and the platinum (Pt) content was measured using inductively coupled plasma mass spectrometry (ICP-MS). This allowed the drug loading (DL) and encapsulation efficiency (EE) to be estimated.
[0088] The ceramide drug content and effective encapsulation efficiency (EE) were determined using HPLC. The prepared liposome solution was concentrated and centrifuged to remove unencapsulated drug. The residual volume was recorded, and 1 ml was transferred to a microcentrifuge tube for freeze-drying. The solution was then reconstituted with 1 ml of HPLC mobile phase and filtered. The ceramide drug content per ml of liposome solution was measured by high-performance liquid chromatography (HPLC), from which the actual drug content and effective encapsulation efficiency (EE) were calculated. UV measurement was performed at a wavelength of 230 nm, a flow rate of 1 ml / min, and a mobile phase of ACN / MeOH = 3 / 7 (v / v). A ceramide signal was observed at approximately 6 minutes. The area of the signal was calculated and applied to the calibration curve to deduce the drug weight, which in turn allowed the drug loading efficiency (DL) and effective encapsulation efficiency (EE) to be estimated.
[0089] Table 4. Drug loading efficiency (DL) and effective encapsulation efficiency (EE) of nanoliposomes with or without ceramide (C) and / or cisplatin (P)
[0090]
[0091] a The effective encapsulation efficiency (EE) of ceramide was determined by HPLC.
[0092] b The drug loading rate (DL) and effective encapsulation efficiency (EE) of cisplatin were determined by ICP-MS.
[0093]
[0094] HPLC and ICP-MS analysis revealed that the nanoliposomes can effectively encapsulate both hydrophilic and hydrophobic drugs. The nanoliposomes achieved an effective encapsulation efficiency of 99% for ceramide and 70% for cisplatin.
[0095] Example 7. Preparation of Glucosamine-labeled Ceramide Nanoliposomes Carrying Paclitaxel
[0096] Dipalmitoylphosphatidylcholine (DPPC), glucosamine-cholesterol synthesized using the method described in Example 1, cholesterol, and ceramide were added to a concentration bottle at the molar ratios shown in Table 5 below. Dissolved in dichloromethane and mixed thoroughly. The dichloromethane was removed using a cycloconcentrator, allowing a thin film to form on the bottom of the concentration bottle. The solution was then placed in a vacuum oven for one hour. Solvent (A) 5ml PBS + 1.5ml Docetaxel (EtOH / PBS = 1:1 (v / v)) and solvent (B) 5ml PBS were prepared in advance and preheated to 60°C. 15ml of ether was added to the concentration bottle and ultrasonically shaken until a thin film was evenly dispersed in the ether. Solvent (A) was then added and ultrasonically shaken and vortexed for several seconds. The ether was then removed using a cycloconcentrator. Solvent (B) was added and the mixture was placed in an oven at 60°C for one hour. The solution was then passed through a 0.22-μm PVDF filter (Millipore, Darmstadt, Germany) twice and a 0.1-μm PVDF filter (Millipore, Darmstadt, Germany) twice, to obtain glucosamine-labeled ceramide nanoliposomes numbered DL1.5 carrying paclitaxel.
[0097] Table 5 Composition of glucosamine-labeled ceramide nanoliposomes carrying paclitaxel
[0098]
[0099] The drug content and effective encapsulation efficiency (EE) of paclitaxel were determined using HPLC. After the prepared liposome solution was concentrated and centrifuged to remove unencapsulated drug, the residual volume was recorded and 1 ml was transferred to a microcentrifuge tube for freeze-drying. The solution was then reconstituted with 1 ml of HPLC mobile phase and filtered. The paclitaxel content in 1 ml of liposome solution was measured by high-performance liquid chromatography (HPLC), from which the actual drug content and effective encapsulation efficiency were calculated. UV measurement was performed at a wavelength of 274 nm, a flow rate of 1 ml / min, and a mobile phase of ACN / H₂O = 3 / 1 (v / v). The paclitaxel signal was detected at approximately 6 minutes. The area of the signal was calculated and inserted into the calibration curve to deduce the drug weight, thereby estimating the drug loading (DL) and effective encapsulation efficiency (EE). The calculation formulas are as described in Example 6.
[0100] Table 6. Particle size, surface charge, polydispersity index (PDI), drug loading efficiency (DL), and effective encapsulation efficiency (EE) of glucosamine-labeled ceramide nanoliposomes carrying paclitaxel
[0101] serial number <![CDATA[Particle size a (nm)]]> <![CDATA[PDI a ]]> <![CDATA[Kcps a ]]> <![CDATA[Zeta a (mV)]]> <![CDATA[DL b (w.t.%)]]> <![CDATA[EE b (w.t.%)]]> DL 0.375 140.6±4.6 0.150±0.010 304.8±134.2 -23.6±3.5 3.6±1.0 61.2±16.3 DL 0.75 146.5±14.1 0.140±0.014 225.3±16.9 -30.8±7.5 5.04 27.8±15.7 DL 1.5 145.1±12.4 0.135±0.020 223.5±54.1 -29.9±5.3 7.21 26.9±8.5
[0102] a Particle size, particle size dispersion (PDI) and surface charge were measured using DLS.
[0103] b The drug loading efficiency (DL) and effective encapsulation efficiency (EE) of paclitaxel in Europe were determined by HPLC.
[0104] The morphology of the obtained nanoliposomes was observed using a JEOL JEM-2000EX II transmission electron microscope (JEOL Inc., Peabody, MA) after staining with 2% uranyl acetate. Figure 13 The results of transmission electron microscopy observations show that the glucose-labeled cisplatin nanoliposomes obtained in this example with or without ceramide can maintain a good intact morphology under physiological conditions, with a spherical structure of lipid bilayer membrane and uniform size.
[0105] In summary, the present invention first synthesizes monosaccharide-labeled cholesterol and combines it with a phospholipid, an active drug, and, optionally, unlabeled cholesterol to produce surface-labeled monosaccharide-labeled nanoliposome drug delivery particles. Cell and animal experiments have demonstrated that the monosaccharide-labeled nanoliposomes of the present invention are capable of specifically targeting and delivering the drug to target cancer cells and cancer stem cells. They can also enter target cells via endocytosis, resulting in direct toxicity or suppression of stemness gene expression, making them suitable for the preparation of targeted therapy nanoparticles. Furthermore, in vivo administration experiments have demonstrated that the monosaccharide-labeled nanoliposomes of the present invention do not produce adverse side effects in administered animals, while effectively inhibiting tumor growth and cancer cell metastasis. Furthermore, when administered in combination with clinical anticancer drugs or radiotherapy, they exhibit synergistic tumor suppression and prevent cancer stem cells from developing resistance to anticancer drugs.
[0106] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of implementation of the patent of the present invention. In other words, simple equal changes and modifications made according to the protection scope of the patent application of the present invention and the content of the invention description are still within the scope of the patent of the present invention.
Claims
1. A monosaccharide molecule-labeled nanoliposome drug delivery system, characterized in that: At least comprising: a compound represented by the following chemical formula I and a phospholipid: [Chemical Formula I] Wherein, the phospholipid is dipalmitoylphosphatidylcholine.
2. The monosaccharide molecule-labeled nanoliposome drug delivery system according to claim 1, characterized in that: The size of the nanoliposomes is between 120-140 nm and has a surface charge between -3 and -15 mV.
3. The monosaccharide molecule-labeled nanoliposome drug delivery system according to claim 1, characterized in that: Further comprising an unmodified cholesterol.
4. The monosaccharide molecule-labeled nanoliposome drug delivery system according to claim 1, characterized in that: An anticancer drug is further contained in the hollow cavity of the liposome.
5. The monosaccharide molecule-labeled nanoliposome drug delivery system according to claim 4, characterized in that: The anticancer drug is selected from cisplatin, paclitaxel, europaclitaxel and a combination thereof.
6. A method for preparing a monosaccharide molecule-labeled nanoliposome drug delivery system as claimed in claim 1, characterized in that: It contains: Synthesize a compound represented by the following chemical formula I; Mixing a phospholipid, an optional cholesterol and the compound represented by the chemical formula I into a mixture; The mixture is prepared into nano-micro liposomes having a single lipid bilayer and a certain size by thin film hydration method, solvent dispersion method, organic solvent injection method, surfactant method, thin film extrusion method or French high pressure method; [Chemical Formula I] 7. The method according to claim 6, characterized in that The phospholipid and the compound represented by the chemical formula I are mixed in a ratio of 50-60 mmole% of phospholipid, 20-48 mmole% of cholesterol and 2-20 mmole% of the compound represented by the chemical formula I.
8. A targeted therapy nanomedicine liposome, characterized in that: The invention comprises: the monosaccharide molecule-labeled nanoliposome drug delivery system as claimed in claim 1 and a drug embedded in the lipid bilayer of the delivery system.
9. The targeted therapy nano drug liposome according to claim 8, characterized in that: The nanoliposomes have a size between 80-160 nm and a surface charge between -10 and -45 mV.
10. The targeted therapy nano drug liposome according to claim 8, characterized in that: This drug is a ceramide.
11. A method for preparing the targeted therapeutic nanomedicine liposome as claimed in claim 8, characterized in that: Include: Synthesize a compound represented by the following chemical formula I; Mixing a phospholipid, the compound represented by the chemical formula I and a drug; The mixture is prepared into nano-micro liposomes having a single lipid bilayer and a certain size by thin film hydration method, solvent dispersion method, organic solvent injection method, surfactant method, thin film extrusion method or French high pressure method; [Chemical Formula I] 12. The method according to claim 11, characterized in that The phospholipid, the compound represented by the chemical formula I and the drug are mixed in a ratio of 52-77 mmole% of the phospholipid, 17-23 mmole% of the compound represented by the chemical formula I and 6-25 mmole% of the ceramide.
13. A pharmaceutical composition, characterized in that: The invention comprises the monosaccharide molecule-labeled nanoliposome drug delivery system as claimed in claim 1 or the targeted therapy nanomedicine liposome as claimed in claim 8 and a pharmaceutically acceptable substrate, carrier or excipient.
14. The pharmaceutical composition according to claim 13, wherein The substrate is selected from polysaccharides, proteins, synthetic polymers or mixtures thereof.
15. The pharmaceutical composition according to claim 13, wherein The anticancer drug is selected from cisplatin, paclitaxel, europaclitaxel, and combinations thereof.
16. The pharmaceutical composition according to claim 13, wherein It is used in cancer treatment.
17. The pharmaceutical composition according to claim 16, wherein The cancer treatment is selected from cancer stem cell treatment, drug-resistant cancer cell treatment, radiation-resistant cancer cell treatment or a combination thereof.
